BioSpecifics Technologies (NASDAQ: BSTC) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare BioSpecifics Technologies to related businesses based on the strength of its earnings, risk, dividends, institutional ownership, profitability, analyst recommendations and valuation.

Risk and Volatility

BioSpecifics Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, BioSpecifics Technologies’ peers have a beta of 8.24, suggesting that their average share price is 724% more volatile than the S&P 500.

Profitability

This table compares BioSpecifics Technologies and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies 42.40% 19.11% 16.84%
BioSpecifics Technologies Competitors -5,311.02% -218.41% -39.47%

Earnings and Valuation

This table compares BioSpecifics Technologies and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioSpecifics Technologies $26.25 million $11.37 million 27.15
BioSpecifics Technologies Competitors $284.49 million $34.10 million 73.89

BioSpecifics Technologies’ peers have higher revenue and earnings than BioSpecifics Technologies. BioSpecifics Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioSpecifics Technologies and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSpecifics Technologies 0 0 1 0 3.00
BioSpecifics Technologies Competitors 874 3237 11724 233 2.70

BioSpecifics Technologies presently has a consensus target price of $65.00, suggesting a potential upside of 50.57%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.86%. Given BioSpecifics Technologies’ stronger consensus rating and higher probable upside, equities research analysts plainly believe BioSpecifics Technologies is more favorable than its peers.

Insider & Institutional Ownership

55.9% of BioSpecifics Technologies shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.5% of BioSpecifics Technologies shares are owned by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

BioSpecifics Technologies beats its peers on 8 of the 13 factors compared.

About BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.